Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gianfranco Miceli"'
Autor:
Fabiola, Atzeni, Elisabetta, Gerratana, Sara, Bongiovanni, Rossella, Talotta, Gianfranco, Miceli, Fausto, Salaffi, Piercarlo, Sarzi-Puttini
There is a lack of real-life clinical data for biosimilar etanercept, an anti-TNF blocking fusion protein. We describe the comparable efficacy and safety of originator and biosimilar etanercept in rheumatoid arthritis (RA) patients in a real-life cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3fd4472fa806590b9099764bc38ce372
http://hdl.handle.net/11570/3212626
http://hdl.handle.net/11570/3212626
Autor:
Gianfranco Miceli, Donatella Sangari, Elisabetta Gerratana, Fabiola Atzeni, Ignazio Francesco Masala, Laura La Corte, Valeria Nucera, Manuela Giallanza
Publikováno v:
Expert Opinion on Biological Therapy
SARS-CoV-2 is a novel coronavirus that was first isolated from a group of patients hospitalized with pneumonia in China at the end of 2019, and, in February 2020, the syndrome it caused was named coronavirus disease 2019 (COVID-19) by the World Healt
Autor:
Elisabetta Gerratana, Ignazio Francesco Masala, Mariateresa Cirillo, L. Boccassini, Valeria Nucera, Donatella Sangari, Fabiola Atzeni, Francesca Marino, Gianfranco Miceli
Publikováno v:
Expert opinion on drug safety. 19(6)
More than 15 years after its introduction, there is still no agreement as to whether anti-TNF treatment increases the risk of developing infections, cardiovascular or neurological diseases, or auto-antibodies. Anti-TNF drugs reduce inflammation and s
Autor:
Donatella Sangari, Fabiola Atzeni, Gianfranco Miceli, Francesca Marino, Valeria Nucera, Elisabetta Gerratana, Ignazio Francesco Masala, Alessia Fiorenza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::600296e3a83c361175dea0713246838e
http://hdl.handle.net/11570/3151561
http://hdl.handle.net/11570/3151561